Voyager Therapeutics Reports It, Collaborator Neurocrine Biosciences Temporarily Paused Screening Of New Patients In RESTORE-1 Trial; Will Resume When Cos. Can Determine Screening Will Be Safety, Effective
Benzinga Newsdesk